Market Newsdesk

VANCOUVER, BC, Dec. 17, 2020 /CNW/ – Trading resumes in:

Company: Voyager Digital Ltd.

CSE Symbol: VYGR

All Issues: No

Resumption (ET): 3:33:46 PM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC)

OVERLAND PARK, Kan., Dec. 17, 2020 /PRNewswire/ — QTS Realty Trust (NYSE: QTS), a leading provider of hybrid colocation and mega scale data center solutions, today announced the appointment of Joan A. Dempsey to its Board of Directors as a new independent director, effective immediately.   

Ms. Dempsey brings over 35 years of consulting and operational experience, primarily working with federal government entities. Ms. Dempsey currently serves as Senior Executive Advisor to the Booz Allen Hamilton Chief Executive Officer. Previously, she served as Executive Vice President and Senior Partner at Booz Allen Hamilton for 12 years where she led the company’s operations and strategy within the defense, homeland security and intelligence sectors. Ms. Dempsey has extensive senior government and professional services expertise developing, managing and overseeing advanced technology programs, including cyber security and mitigating program and technology risks.

Ms. Dempsey’s experience, together with existing Board members Peter Marino and Wayne Rehberger, both of whom bring expertise and operating experience within the federal vertical, further demonstrates QTS’ continued focus and momentum in providing highly secure data center solutions for federal government customers.

“I’m pleased to welcome Joan to the QTS Board of Directors. Her extensive professional experience serving our country and working directly with federal government agencies on strategic technology initiatives will provide important insight and perspective to the QTS Board and executive management team,” said Chad Williams, Chairman and Chief Executive Office of QTS.

Following the appointment of Ms. Dempsey as a new independent director, QTS’ Board will comprise eleven directors, ten of whom are independent, reflecting QTS’ commitment to regular Board refreshment and independence.

About Joan A. Dempsey
Ms. Dempsey brings over 35 years of consulting and operational experience, primarily working with federal government entities. Ms. Dempsey currently serves as Senior Executive Advisor to the Booz Allen Hamilton Chief Executive Officer. Previously, she served as Executive Vice President and Senior Partner at Booz Allen Hamilton for 12 years where she led the company’s operations and strategy within the defense, homeland security and intelligence sectors. Prior to joining Booz Allen Hamilton in 2005, Ms. Dempsey spent a 25-year career serving in the federal government, including two political appointments. She served as the deputy director of Central Intelligence for Community Management during President Bill Clinton’s administration and served as the executive director of the President’s Intelligence Advisory Board during President George W. Bush’s administration. Ms. Dempsey also spent 17 years as a senior civilian in the Department of Defense (DoD) as deputy director of intelligence at the Defense Intelligence Agency, as the deputy assistant secretary of defense for intelligence and security, and as the designated (acting) assistant secretary of command, control, communications and intelligence.

Ms. Dempsey was the 2004 recipient of the Intelligence Security Affairs Support Association William O. Baker Award, an honor she shares with two former secretaries of defense, three members of Congress, and two former directors of central intelligence. In addition to the DoD Distinguished Civilian Service Award, she is a recipient of the National Intelligence Medal of Achievement, and The American University Roger W. Jones Award for Executive Leadership.

About QTS
QTS Realty Trust, Inc. (NYSE: QTS) is a leading provider of data center solutions across a diverse footprint spanning more than 7 million square feet of owned mega scale data center space within North America and Europe. Through its software-defined technology platform, QTS is able to deliver secure, compliant infrastructure solutions, robust connectivity and premium customer service to leading hyperscale technology companies, enterprises, and government entities. Visit QTS at www.qtsdatacenters.com, call toll-free 877.QTS.DATA or follow on Twitter @DataCenters_QTS.

Investor Relations Contact:

Stephen Douglas, EVP Finance
[email protected]

Media Contact:

Carter B. Cromley

(703) 861-7245
[email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/qts-realty-trust-inc-appoints-joan-a-dempsey-to-board-of-directors-301195597.html

SOURCE QTS Realty Trust, Inc.

LONDON, Dec. 17, 2020 /PRNewswire/ — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of GlaxoSmithKline’s Advair Diskus^®1 (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.

Hikma worked with Vectura Group, a UK based provider of innovative inhaler drug delivery solutions, to develop the proprietary dry powder inhaler and formulation technology.

According to IQVIA, US sales of Fluticasone Propionate and Salmeterol Inhalation Powder USP, 100mcg/50mcg and 250mcg/50mcg, were approximately $2 billion in the 12 months ending September 2020.

Siggi Olafsson, Chief Executive Officer of Hikma, said “The approval of our generic version of Advair Diskus^® marks an important milestone in our strategy to develop more complex respiratory products.  Through the unwavering dedication of our employees and close collaboration with the Vectura team, we have developed a high quality and substitutable generic product for Advair Diskus^® that will improve availability of this critical medicine. We are very pleased to have now launched this product and will leverage the investments we have made and the experience we have gained through this process to develop a range of respiratory and other complex treatment options for patients and healthcare providers, helping us to continue to put better health, within reach, every day.”

Enquiries 

                                                         

About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody’s)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people’s lives. We’re committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

Important Safety Information for
Fluticasone Propionate and Salmeterol Inhalation Powder USP,
100mcg/50mcg, 250mcg/50mcg
:

Contraindications
The use of fluticasone propionate and salmeterol inhalation powder is contraindicated in the following conditions:

• Primary treatment of status asthmaticus or other acute episodes of asthma or chronic obstructive pulmonary disease (COPD) where intensive measures are required.
• Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone propionate, salmeterol or any of the excipients.

Warnings and Precautions

Warnings While Using This Medicine:
Tell your doctor if you are pregnant or breastfeeding, or if you have liver disease, cataracts, diabetes, glaucoma, heart disease, high blood pressure, heart rhythm problems, thyroid problems, seizures, or osteoporosis. Tell your doctor about any immune system problems or infections, including herpes simplex in your eye, tuberculosis, or parasites. Tell your doctor if you have been exposed to chickenpox or measles.

This medicine may cause the following problems:
Increased risk of asthma-related hospital stays, intubations, and death
Increased trouble breathing right after use (paradoxical bronchospasm)
Increased risk of pneumonia in people who have COPD
Increased risk of infection, including fungus infection in the mouth (thrush)
Low bone mineral density, which may lead to osteoporosis
Cataracts, glaucoma, or other vision problems
Slow growth in children
Adrenal gland problems

This medicine will not stop an asthma attack that has already started. You should have another medicine to use in case of an acute asthma attack or COPD flare-up. Tell your doctor right away if your condition gets worse or you need to use your other medicine more often than usual.
If any of your asthma medicines do not seem to be working as well as usual, call your doctor right away. Do not change your doses or stop using your medicines without asking your doctor.
Tell any doctor or dentist who treats you that you are using this medicine.
Call your doctor if your symptoms do not improve or if they get worse.
Your doctor will check your progress and the effects of this medicine at regular visits. Keep all appointments.
Keep all medicine out of the reach of children. Never share your medicine with anyone.

Possible Side Effects While Using This Medicine:

Call your doctor right away if you notice any of these side effects:
Allergic reaction: Itching or hives, swelling in your face or hands, swelling or tingling in your mouth or throat, chest tightness, trouble breathing
Changes in skin color, dark freckles, easy bruising, muscle weakness, round or puffy face
Chest pain, trouble breathing
Dry mouth, increased thirst, muscle cramps, nausea, vomiting
Eye pain or trouble seeing
Fast, pounding, or uneven heartbeat
Fever, chills, cough, runny or stuffy nose, sore throat, body aches
Tremors, nervousness, or shaking
Unusual tiredness or weakness
Worsening of breathing problems

If you notice these less serious side effects, talk with your doctor:
Headache
Hoarseness, voice changes
White patches inside the mouth or throat

If you notice other side effects that you think are caused by this medicine, tell your doctor.

Fluticasone propionate and salmeterol inhalation powder contains salmeterol. Long-acting beta₂-adrenergic agonist (LABA) medicines such as salmeterol when used alone increase the risk of hospitalizations and death from asthma problems. Fluticasone propionate and salmeterol inhalation powder contains an inhaled corticosteroid (ICS) and a LABA. When  a fixed-dise combination ICS and a LABA are used together, there is not a significant increased risk in hospitalizations and death from asthma problems compared with ICS alone.

Do not use other medicines that contain a LABA for any reason. Ask your healthcare provider or pharmacist if any of your other medicines are LABA medicines.

Do not use fluticasone propionate and salmeterol inhalation powder to relieve sudden breathing problems. Always have a rescue inhaler with you to treat sudden symptoms.

Do not use fluticasone propionate and salmeterol inhalation powder if you have a severe allergy to milk proteins. Ask your healthcare provider if you are not sure.

Do not use fluticasone propionate and salmeterol inhalation powder if you are allergic to fluticasone propionate, salmeterol or any of the ingredients in fluticasone propionate and salmeterol inhalation powder. Ask your healthcare provider if you are not sure.

Do not use fluticasone propionate and salmeterol inhalation powder more often or at a higher dose than prescribed.

Rinse your mouth with water without swallowing after each dose of fluticasone propionate and salmeterol inhalation powder.

Call your healthcare provider or get medical care right away if: 
–       your breathing problems get worse or you need to use your rescue inhaler more often than usual.
–       your rescue inhaler does not work as well to relieve your symptoms.
–       you need to use 4 or more inhalations of your rescue inhaler in 24 hours for 2 or more days in a row.
–       you use 1 whole canister of your rescue inhaler in 8 weeks.
–       your peak flow meter results decrease. Your healthcare provider will tell you the numbers that are right for you.
–       you have asthma and your symptoms do not improve after using regularly for 1 week

Fluticasone propionate and salmeterol inhalation powder can cause serious side effects, including:

• Fungal infection in your mouth or throat (thrush). Rinse your mouth with water without swallowing after each dose of fluticasone propionate and salmeterol inhalation powder.
• Pneumonia. People with COPD have a greater chance of getting pneumonia. Fluticasone propionate and salmeterol inhalation powder may increase this risk. Call your healthcare provider right away if you have an increase in mucus (sputum) production, change in mucus color, fever, chills, increased cough or increased breathing problems.
• Weakened immune system and greater chance of getting infections (immunosuppression). Fluticasone propionate and salmeterol inhalation powder may make you more prone to infection. Chickenpox and measles, for example, can have a more serious or even fatal course in children or adults using corticosteroids.
• Reduced adrenal function (adrenal insufficiency). This can happen when you stop taking oral corticosteroid medicines (like prednisone) and start taking a medicine containing an inhaled steroid (like fluticasone propionate and salmeterol inhalation powder). During this transition period, when your body is under stress such as fever, trauma, infection, surgery or more severe COPD symptoms, adrenal insufficiency can get worse and may cause death. Symptoms of adrenal insufficiency include feeling tired, lack of energy, weakness, nausea and vomiting and low blood pressure.
• Sudden breathing problems immediately after inhaling your medicine. If you have sudden breathing problems immediately after inhaling your medicine, stop using fluticasone propionate and salmeterol inhalation powder and call your healthcare provider right away.
• Serious allergic reactions. Call your healthcare provider or get emergency medical care right away if you have any of the following symptoms of a serious allergic reaction: rash; hives; swelling of the mouth, face and/or tongue; breathing problems.
• Effects on the heart. Call your healthcare provider if you have an increase in blood pressure, fast or irregular heartbeat or chest pain.
• Effects on the nervous system. Call your healthcare provider if you have tremor or nervousness.
• Bone thinning or weakness (osteoporosis). Get regular bone density screenings if you have or are at risk for osteoporosis treated with established standards of care.
• Slowed growth in children. Have your child’s growth checked regularly by a healthcare provider while using fluticasone propionate and salmeterol inhalation powder.
• Eye problems. Tell your healthcare provider if you have glaucoma, increased pressure in your eye, cataracts or other changes in vision. Get regular eye exams while using fluticasone propionate and salmeterol inhalation powder.
• Changes in laboratory blood levels (sugar, potassium, certain types of white blood cells). Get blood tests at your healthcare provider’s recommendation.

Common Side Effects

• Common side effects for asthma include upper respiratory tract infection, throat irritation, hoarseness and voice changes, thrush in your mouth or throat, bronchitis, cough, headache, and nausea and vomiting. In children with asthma, infections in the ear, nose, and throat are common.
• Common side effects for COPD include thrush in your mouth or throat, throat irritation, hoarseness and voice changes, viral respiratory infections, headache, and muscle and bone pain.

Common side effects of fluticasone propionate and salmeterol inhalation powder in patients with COPD include thrush in the mouth or throat, throat irritation, hoarseness and voice changes, viral respiratory infections, headache and muscle and bone pain.

These are not all the possible side effects of fluticasone propionate and salmeterol inhalation powder. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Drug Interactions
Tell your healthcare provider about all of your medical conditions and about all the medicines you take, as fluticasone propionate and salmeterol inhalation powder can interact with other medicines and may cause side effects, in some cases severe:

Drugs and Foods to Avoid:

Ask your doctor or pharmacist before using any other medicine, including over-the-counter medicines, vitamins, and herbal products.
Some foods and medicines can affect how fluticasone/salmeterol works. Tell your doctor if you are using any of the following:
Blood pressure medicine
Diuretic (water pill)
Medicine to treat depression or an MAO inhibitor within the past 2 weeks (including nefazodone)
Medicine to treat HIV or AIDS (including atazanavir, indinavir, nelfinavir, ritonavir, saquinavir)
Medicine to treat an infection (including clarithromycin, itraconazole, ketoconazole, telithromycin)
Seizure medicine

Pregnancy and Breastfeeding
Tell your healthcare provider if you are pregnant, plan to become pregnant or are breastfeeding.

Dosage and Administration
Fluticasone propionate and salmeterol inhalation powder should be administered as 1 inhalation twice daily by the orally inhaled route only. After inhalation, the patient should rinse his/her mouth with water without swallowing to help reduce the risk of oropharyngeal candidiasis.

More frequent use or taking more than 1 inhalation twice daily of the prescribed strength of fluticasone propionate and salmeterol inhalation powder is not recommended.

Do not use additional LABA for any reason.

Indications and Usage

Treatment of Asthma
Fluticasone propionate and salmeterol inhalation powder is indicated for the twice-daily treatment of asthma in patients aged 4 years and older.

Important Limitation of Use:

Fluticasone propionate and salmeterol inhalation powder is NOT indicated for the relief of acute bronchospasm.

Maintenance Treatment of COPD
Fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. Fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.

Important Limitation of Use:


Fluticasone propionate and salmeterol inhalation powder is NOT indicated for the relief of acute bronchospasm.

For more information about fluticasone propionate and salmeterol inhalation powder, please see the full Prescribing Information and Medication Guide, which you can find in the full press release published on our website at https://www.hikma.com/newsroom/#pageRS=1.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Distributed by: Hikma Pharmaceuticals USA Inc., Berkeley Heights, NJ, 07922

Document identification number: WW40040

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/hikma-launches-generic-advair-diskus-following-fda-approval-301195605.html

SOURCE Hikma Pharmaceuticals USA Inc.

CHICAGO, Dec. 17, 2020 /PRNewswire/ — Cboe Global Markets, Inc. (Cboe: CBOE), a market operator and global trading solutions provider, today announced its Board of Directors elected Ivan Fong, Senior Vice President, General Counsel and Secretary of 3M Company, and Alexander J. Matturri, Jr. former Chief Executive Officer of S&P Dow Jones Indices LLC, as new members to its Board of Directors.   

Mr. Fong and Mr. Matturri are elected to fill a vacancy on the Cboe Global Markets board and increase the number of directors to 15.

Ed Tilly, Chairman, President and Chief Executive Officer of Cboe Global Markets, said: “We are pleased to welcome Ivan Fong and Alex Matturri to Cboe Global Markets’ board of directors. Each brings a wealth of knowledge and experience that will add to the leadership and counsel of our board. Their addition strengthens our ability to execute strategic initiatives that grow our global business, serve the needs of our customers and deliver sustainable returns and long-term value to our shareholders.” 

Mr. Fong is currently Senior Vice President, General Counsel and Secretary of 3M Company, a position he has held since June 2019. Previously, he served as Senior Vice President, Legal Affairs and General Counsel of 3M Company from 2012 to 2019. Prior to joining 3M Company, Mr. Fong was General Counsel of the United States Department of Homeland Security from 2009 to 2012 and the Chief Legal Officer and Secretary of Cardinal Health, Inc. from 2005 to 2009. Mr. Fong holds an S.B. degree in Chemical Engineering and an S.M. degree in Chemical Engineering Practice from Massachusetts Institute of Technology, a J.D. degree from Stanford University, and a Bachelor of Civil Law from Oxford University.

Mr. Matturri is the retired Chief Executive Officer of S&P Dow Jones Indices LLC (S&P), a position he held from July 2012 to June 2020. Previously, he served as Executive Managing Director and Head of S&P Indices from 2007 to 2012. Prior to joining S&P, Mr. Matturri served as Senior Vice President and Director of Global Equity Index Management at Northern Trust Global Investments from 2003 to 2007. From 2000 to 2003, he was Director and Senior Index Investment Strategist at Deutsche Asset Management. Mr. Matturri holds a B.S. degree in Finance from Lehigh University and a J.D. degree from Syracuse University. Mr. Matturri holds the Chartered Financial Analyst designation.

About Cboe Global Markets, Inc.

Cboe Global Markets (Cboe: CBOE) provides cutting-edge trading and investment solutions to market participants around the world. The company is committed to defining markets through product innovation, leading edge technology and seamless trading solutions.

The company offers trading across a diverse range of products in multiple asset classes and geographies, including options, futures, U.S., Canadian and European equities, exchange-traded products (ETPs), global foreign exchange (FX) and volatility products based on the Cboe Volatility Index® (VIX® Index), recognized as the world’s premier gauge of U.S. equity market volatility.

Cboe’s subsidiaries include the largest options exchange and the third largest stock exchange operator in the U.S. In addition, the company operates one of the largest stock exchanges by value traded in Europe, and owns EuroCCP, a leading pan-European equities clearing house. Cboe also is a leading market globally for ETP listings and trading.

The company is headquartered in Chicago with a network of domestic and global offices across the Americas, Europe and Asia, including main hubs in New York, London, Kansas City and Amsterdam. For more information, visit www.cboe.com.  

CBOE-C
CBOE-OE

Cboe®, Cboe Global Markets®, Cboe Volatility Index®, and VIX® are registered trademarks of Cboe Exchange, Inc.

View original content to download multimedia:http://www.prnewswire.com/news-releases/cboe-global-markets-announces-election-of-ivan-fong-and-alexander-j-matturri-jr-to-board-of-directors-301195598.html

SOURCE Cboe Global Markets, Inc.

TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ — Ellomay Capital Ltd. (NYSE American: ELLO) (TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable energy and power projects in Europe and Israel, today announced that at the extraordinary general meeting of the Company’s shareholders, held on December 17, 2020 (the “EGM“), the following proposals were adopted and approved by the required majority (including the special majority required in connection with proposals 1, 3, and 5-7):

1. Election of Mr. Daniel Vaknin as a new external director for an initial three-year term, commencing December 20, 2020;
2. Approval of terms of service of Mr. Daniel Vaknin, the external director nominee;
3. Approval of grant of options to Mr. Daniel Vaknin, the external director nominee;
4. Approval of provision of an exemption to Mr. Daniel Vaknin, the external director nominee;
5. Approval of terms of service of Mr. Ehud Gil, a member of the Board of Directors;
6. Approval of grant of options to Mr. Ehud Gil, a member of the Board of Directors; and
7. Approval of provision of an exemption to Mr. Ehud Gil, a member of the Board of Directors.

For more information, please see the Company’s Amended Notice and Proxy Statement relating to the EGM furnished on Form 6-K to the Securities and Exchange Commission on November 27, 2020.

About Ellomay Capital Ltd.

Ellomay is an Israeli based company whose shares are registered with the NYSE American and with the Tel Aviv Stock Exchange under the trading symbol “ELLO”. Since 2009, Ellomay Capital focuses its business in the renewable energy and power sectors in Europe and Israel.

To date, Ellomay has evaluated numerous opportunities and invested significant funds in the renewable, clean energy and natural resources industries in Israel, Italy and Spain, including:

• Approximately 7.9MW of photovoltaic power plants in Spain and a photovoltaic power plant of approximately 9 MW in Israel;
• 9.375% indirect interest in Dorad Energy Ltd., which owns and operates one of Israel’s largest private power plants with production capacity of approximately 860MW, representing about 6%-8% of Israel’s total current electricity consumption;
• 51% of Talasol, which is involved in a project to construct a photovoltaic plant with a peak capacity of 300MW in the municipality of Talaván, Cáceres, Spain;
• Groen Gas Goor B.V., Groen Gas Oude-Tonge B.V. and Groen Gas Gelderland B.V., project companies operating anaerobic digestion plants in the Netherlands, with a green gas production capacity of approximately 3 million, 3.8 million and 9.5 million (with a license to produce 7.5 million) Nm3 per year, respectively;
• 75% of Ellomay Pumped Storage (2014) Ltd. (including 6.67% that are held by a trustee in trust for us and other parties), which is involved in a project to construct a 156 MW pumped storage hydro power plant in the Manara Cliff, Israel.

Ellomay Capital is controlled by Mr. Shlomo Nehama, Mr. Hemi Raphael and Mr. Ran Fridrich. Mr. Nehama is one of Israel’s prominent businessmen and the former Chairman of Israel’s leading bank, Bank Hapohalim, and Messrs. Raphael and Fridrich both have vast experience in financial and industrial businesses. These controlling shareholders, along with Ellomay’s dedicated professional management, accumulated extensive experience in recognizing suitable business opportunities worldwide. Ellomay believes the expertise of Ellomay’s controlling shareholders and management enables the Company to access the capital markets, as well as assemble global institutional investors and other potential partners. As a result, we believe Ellomay is capable of considering significant and complex transactions, beyond its immediate financial resources.

For more information about Ellomay, visit http://www.ellomay.com.

Information Relating to Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company’s management. All statements, other than statements of historical facts, included in this press release regarding the Company’s plans and objectives, expectations and assumptions of management are forward-looking statements.  The use of certain words, including the words “estimate,” “project,” “intend,” “expect,” “believe” and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by the Company’s forward-looking statements, including the impact of COVID-19 virus on the Company’s operations and projects, including in connection with steps taken by authorities in countries in which the Company operates, regulatory changes, changes in the supply and prices of resources required for the operation of the Company’s facilities (such as waste and natural gas) and in the price of oil, changes in demand and technical and other disruptions in the operations or construction of the power plants owned by the Company in addition to other risks and uncertainties associated with the Company’s business that are described in greater detail in the filings the Company makes from time to time with Securities and Exchange Commission, including its Annual Report on Form 20-F. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Kalia Weintraub 
CFO
Tel: +972 (3) 797-1111
Email: [email protected]

 

 

 

 

View original content:http://www.prnewswire.com/news-releases/ellomay-capital-announces-results-of-2020-extraordinary-general-meeting-of-shareholders-301195500.html

SOURCE Ellomay Capital Ltd

LONDON, Dec. 17, 2020 /PRNewswire/ — Europe, Univar B.V., a subsidiary of Univar Solutions Inc. (NYSE: UNVR) (“Univar Solutions” or “the Company”), a global chemical and ingredient distributor and provider of value-added services, announced today that Dow Coating Materials has authorized Univar Solutions as its distributor in the United Kingdom and Ireland for all coatings applications and in Turkey for industrial coatings applications. This includes all products in the PRIMAL™, EVOQUE™, MAINCOTE™, FASTRACK™ ROPAQUE™, OROTAN™, and ACRYSOL™ brands, each well-recognized and proven products in the coatings market. This portfolio of acrylic binders, styrene acrylic binders, rheology modifiers, and dispersants is produced in Europe and provides solutions across architectural, industrial, and wood coating applications.

“We are excited to deepen our distribution relationship with the Dow Coating Materials business from Dow. Univar Solutions is a global leader in the distribution of specialty chemicals for the coatings industry and our continued collaboration with Dow will provide our customers in the United Kingdom, Ireland, and Turkey with an even more comprehensive product portfolio,” said Joshua Hicks, vice president of global industrial solutions at Univar Solutions. “By bringing together a best-in-class product portfolio with industry leading service and market knowledge, we believe coatings manufacturers in the region will be able to further accelerate their growth.”

The distribution agreement begins January 1, 2021 and expands Univar Solutions specialty portfolio including industry-leading silicones, pigments, fillers, and other resins used in various architectural, industrial, and wood coating applications. Through a global network of solution centers, Univar Solutions consistently provides customers with a comprehensive suite of technical, regulatory, market trend, and sourcing support for the coatings market bringing enterprise level scale and capabilities to the end-use formulation.

“When looking for the right channel partner for our coatings business in the United Kingdom, Ireland, and Turkey we wanted to find a distributor that brings together market leadership, technical innovation, and high-levels of customer service. Univar Solutions clearly demonstrates its leadership in each of these areas,” said Roberto Lazzari, EMEAI distribution manager for Dow Coating Materials. “As global market leaders in the coatings market, Dow and Univar Solutions together are well positioned to deliver business and technical success for our customers.”

About Univar Solutions
Univar Solutions (NYSE: UNVR) is a leading global specialty chemical and ingredient distributor representing a premier portfolio from the world’s leading producers. With the industry’s largest private transportation fleet and North American sales force, unparalleled logistics know-how, deep market and regulatory knowledge, world-class formulation development, and leading digital tools the company is well-positioned to offer tailored solutions and value-added services to a wide range of markets, industries, and applications. Univar Solutions is committed to helping customers and suppliers innovate and grow together. Learn more at UnivarSolutions.com.

About Dow
Dow combines global breadth, asset integration and scale, focused innovation and leading business positions to achieve profitable growth. The company’s ambition is to become the most innovative, customer centric, inclusive and sustainable materials science company. Dow’s portfolio of plastics, industrial intermediates, coatings and silicones businesses delivers a broad range of differentiated science-based products and solutions for its customers in high-growth market segments, such as packaging, infrastructure and consumer care. Dow operates 109 manufacturing sites in 31 countries and employs approximately 36,500 people. Dow delivered sales of approximately 43 billion in 2019. References to Dow or the Company mean Dow Inc. and its subsidiaries. For more information, please visit www.dow.com or follow @DowNewsroom on Twitter.

Forward-Looking Statements
This press release includes certain statements relating to future events and our intentions, beliefs, expectations, and predictions for the future which are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond the Company’s control. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the expectations and assumptions. A detailed discussion of these factors and uncertainties is contained in the Company’s filings with the Securities and Exchange Commission. Potential factors that could affect such forward-looking statements include, among others: the ultimate geographic spread of the COVID-19 pandemic; the duration and severity of the COVID-19 pandemic; actions that may be taken by governmental authorities to address or otherwise mitigate the impact of the COVID-19 pandemic; the potential negative impacts of COVID-19 on the global economy and our customers and suppliers; the overall impact of the COVID-19 pandemic on our business, results of operations and financial condition; other fluctuations in general economic conditions, particularly in industrial production and the demands of our customers; significant changes in the business strategies of producers or in the operations of our customers; increased competitive pressures, including as a result of competitor consolidation; significant changes in the pricing, demand and availability of chemicals; our levels of indebtedness, the restrictions imposed by our debt instruments, and our ability to obtain additional financing when needed; the broad spectrum of laws and regulations that we are subject to, including extensive environmental, health and safety laws and regulations; an inability to integrate the business and systems of companies we acquire, including of Nexeo Solutions, Inc., or to realize the anticipated benefits of such acquisitions; potential business disruptions and security breaches, including cybersecurity incidents; an inability to generate sufficient working capital; increases in transportation and fuel costs and changes in our relationship with third party providers; accidents, safety failures, environmental damage, product quality and liability issues and recalls; major or systemic delivery failures involving our distribution network or the products we carry; operational risks for which we may not be adequately insured; ongoing litigation and other legal and regulatory risks; challenges associated with international operations; exposure to interest rate and currency fluctuations; potential impairment of goodwill; liabilities associated with acquisitions, ventures and strategic investments; negative developments affecting our pension plans and multi-employer pensions; labor disruptions associated with the unionized portion of our workforce; and the other factors described in the Company’s filings with the Securities and Exchange Commission. We caution you that the forward-looking information presented in this press release is not a guarantee of future events or results, and that actual events or results may differ materially from those made in or suggested by the forward-looking information contained in this press release. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “plan,” “seek, “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe” or “continue” or the negative thereof or variations thereon or similar terminology. Any forward-looking information presented herein is made only as of the date of this press release, and the Company does not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise, except as required by law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/univar-solutions-and-dow-coating-materials-announce-new-distribution-agreement-in-the-united-kingdom-ireland-and-turkey-301195536.html

SOURCE Univar Solutions Inc.